On October 23, 2025, H.C. Wainwright reiterated its "Buy" rating for Cidara Therapeutics, Inc. (NASDAQ:CDTX), maintaining its position as a top pick following new influenza data. The stock was priced at $98.27 at the time of this announcement. Cidara Therapeutics is a biotechnology company focused on developing innovative anti-infectives, with a particular emphasis on influenza prevention.
Recently, Cidara presented promising data on its non-vaccine influenza preventative candidate, CD388, at the 10th European Scientific Working Group on Influenza Conference. The presentation highlighted the translational efficacy of CD388, bridging preclinical findings with recent clinical outcomes from the Phase 2b NAVIGATE study. This supports the ongoing Phase 3 ANCHOR trial, which aims to protect vulnerable populations.
Despite the positive developments, CDTX's stock price has decreased by 2.03%, currently priced at $97.31. The stock has fluctuated between a low of $97.15 and a high of $99.25 today. Over the past year, CDTX has seen a high of $121.21 and a low of $11.12, indicating significant volatility.
CDTX has a market capitalization of approximately $2.47 billion, reflecting its position in the biotechnology sector. The trading volume for the day stands at 161,126 shares, suggesting moderate investor interest. As the company progresses with its trials, the market will closely watch for further developments in CD388's efficacy and potential market impact.
